Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

Waldencast exits Obagi Medical for up to $460 million, repays debt, pivots to Milk Makeup.

What the company is saying

Waldencast plc announces the completion of its sale of Obagi Medical to Bridgepoint, highlighting a transaction value of up to $460 million, subject to customary adjustments. The company emphasizes the repayment of all outstanding senior term loan facility, positioning this as a financial reset. Leadership messaging focuses on the continued investment in Milk Makeup, now the sole remaining brand, under President Mazdack Rassi and Executive Chairman Felipe Dutra. The announcement foregrounds leadership transitions, noting that founders Michel Brousset and Hind Sebti, along with CFO Manuel Manfredi, will depart to lead Obagi Medical under Bridgepoint. Allocation of transaction proceeds is flagged as pending Board review, with no specifics provided. The tone remains neutral, with forward-looking statements about strategy and growth for Milk Makeup but no quantification or operational detail. No operational or financial performance data for Milk Makeup or the ongoing business is disclosed.

What the data suggests

The only concrete figure disclosed is the transaction value: up to $460 million for the sale of Obagi Medical, subject to negotiated deductions and customary closing adjustments. Waldencast confirms full repayment of its senior term loan facility, but does not specify the amount repaid or the resulting cash position. There are no revenue, profit, cash flow, or segment performance figures for either the sold or retained businesses. The absence of operational metrics or period-over-period financials prevents assessment of underlying business health or trajectory. Claims about future investment in Milk Makeup and leadership structure are unsupported by data or documentation. The disclosure is limited to the transaction mechanics and leadership changes, offering no insight into ongoing profitability, growth prospects, or capital allocation plans.

Analysis

The announcement is primarily a factual disclosure of the completed sale of Obagi Medical for up to $460 million and the repayment of Waldencast's senior term loan facility. These are realised, milestone events, not aspirational claims. While there are some forward-looking statements about future investment in Milk Makeup and leadership transitions, these are presented in a neutral tone and do not overstate potential benefits or outcomes. No exaggerated language or inflated projections are present, and the announcement avoids promotional phrasing. However, the lack of any profitability or operational metrics for the ongoing business means the true_signal cannot exceed weak_positive. The gap between narrative and evidence is minimal, as the main claims are supported by disclosed facts.

Risk flags

• ●Disclosure risk is high: the announcement omits all operational and financial performance data for the ongoing business, leaving investors unable to assess profitability, cash flow, or growth prospects. This lack of transparency limits visibility into the company’s future earnings power.
• ●Execution risk is elevated: with the departure of founders and the CFO, leadership continuity is disrupted. The new management team must demonstrate its ability to drive Milk Makeup’s growth without the prior leadership’s involvement.
• ●Capital allocation uncertainty: the announcement states that allocation of transaction proceeds is subject to Board review, but provides no detail on intended uses, potential returns, or capital structure. This creates ambiguity around future strategy and shareholder value realization.

Bottom line

Waldencast’s sale of Obagi Medical for up to $460 million and repayment of its senior term loan facility marks a major strategic pivot, leaving Milk Makeup as its sole brand. The announcement delivers a clear financial reset but withholds all operational and financial details about the ongoing business, making it impossible to assess future earnings or growth potential. Leadership transitions introduce further uncertainty, as key founders and the CFO depart. The company’s narrative about investing in Milk Makeup and pursuing future strategies is unsubstantiated by data or specific plans. For investors, this announcement signals a simplified business and improved balance sheet, but the lack of disclosure and clarity on capital allocation or operational performance means the investment thesis now rests entirely on future updates. The most important takeaway: until Waldencast provides transparent financials and a concrete strategy for Milk Makeup, the risk profile remains high and the path to value realization is unclear.

Announcement summary

(NASDAQ: WALD) Waldencast plc announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses). In conjunction with the closing of the transaction, Waldencast repaid all of its outstanding senior term loan facility. The company will continue to invest in its remaining brand, Milk Makeup, under the leadership of President and Co-Founder Mazdack Rassi and oversight from Executive Chairman, Felipe Dutra. Waldencast founders Michel Brousset and Hind Sebti, along with Chief Financial Officer Manuel Manfredi, will transition from the Company to lead Obagi Medical in partnership with Bridgepoint. Felipe Dutra, Executive Chairman of the Board, will serve as the Company’s principal executive officer and principal financial officer. Any further allocation of transaction proceeds remains subject to review by the Board of Directors of the Company. The company projects that future strategies may be pursued and intends to focus on accelerating the global growth of Milk Makeup.

Disagree with this article?